Timeframes Moved Forward as OREX Light Study Continues Enrollment Faster Than Anticipated

Orexigen Therapeutics (NASDAQ:OREX) continues this week’s gains in early trading on Thursday, up roughly 20% to $5.35 since Tuesday. The strength comes from Orexigen’s announcement that its Phase III safety trial of the weight-loss drug Contrave is enrolling much faster than anticipated. Orexigen expects to close enrollment in the fourth quarter of this year; the company announced similar news in July and bumped guidance for enrollment closure to early 2013. The trial is measuring Contrave patients for major adverse cardiovascular events (MACE) but management is unsure when interim data will be available; rapid enrollment should speed up the process. Contrave’s New Drug Application (NDA) was met with a Complete Response Letter from the FDA in 2011, but Orexigen may resubmit the NDA after interim data from the Light Study. The trial has 4,500 patients enrolled and is expected to have a total of 10,000 patients. Contrave is the third weight-loss drug under recent consideration since the approval of Vivus’ (NASDAQ:VVUS) Qsymia, and Arena’s (NASDAQ:ARNA) Belviq. Some of PropThink’s previous articles on these weight-loss drugs are available here and here

Expect the company to continue updates into the end of the year, which should in turn drive shares higher and may offer a swing trade opportunity, as evidenced by stock movement after the July 11 update. The news this week is the second announcement in three months pertaining to faster enrollment in the Light Study.

Additional disclosure: PropThink is a team of editors, analysts, and writers. Use of PropThink's research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at this link.